New York, August 6, 2024 - PRISM MarketView - Recognizing that “rare diseases are only rare if you don’t live with one,” Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced the planned initiation of an investigator-led clinical study in New Zealand to evaluate the safety and efficacy of QRX003 in a pediatric patient with Peeling Skin Syndrome (PSS), a rare autosomal disease with no approved treatment or cure. The clinical-stage specialty pharmaceutical company, is actively evaluating additional clinical sites in other countries with the aim of developing more products that treat rare and orphan diseases.
“We are excited to expand QRX003’s development into this second indication, Peeling Skin Syndrome. This planned initiation represents a key pillar of Quoin’s strategy to expand the clinical testing of QRX003 into other rare and orphan disease indications and we are actively assessing additional opportunities beyond this one.”
Michael Myers, CEO of Quoin Pharmaceuticals
QRX003, Quoin’s most advanced pipeline product, is currently being evaluated in two late-stage clinical trials in the United States as a potential treatment for Netherton Syndrome (NS). With positive initial clinical data, these studies are being conducted under an open Investigational New Drug (IND) application with the Food and Drug Administration (FDA). Quoin is optimistic about receiving U.S. and EU approval in 2025 for NS, and is also exploring opportunities for advancing QRX003 into local Compassionate Use programs and other expedited approval pathways.
A unique “whole body, whole life” topical lotion, QRX003 targets NS hallmarks of skin inflammation and barrier disruption to support a more normalized rate of skin shedding. This could potentially result in the development of a more normally functioning skin barrier and a significant improvement in the quality of life for patients with NS, PSS and other conditions.
Quoin has established a global commercialization and distribution network encompassing 60-plus countries, with additional discussions underway to extend the commercial applicability of QRX003 and other products. The company’s strategic expansion efforts highlight its mission of addressing unmet medical needs and improving patient outcomes in rare and orphan diseases.
For more information about Quoin clinical trials, please visit: https://www.nethertonsyndromeclinicaltrials.com/
About PRISM MarketView:
Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on X.
Disclaimer:
PRISM MarketView is not a registered or licensed broker-dealer or investment adviser and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.
Contact:
Prism MarketView | Stock Market News & Investment Opportunities